sign in sign up
<<
Home , Viral vector vaccine

FOCAL POINT ON RESEARCH IN ASIA ADVERTISEMENT FEATURE

A best shot at global public health response From tuberculosis and pneumonia, to Ebola and Zika, a Chinese biotech firm is DEVELOPING HIGH-QUALITY to address global health challenges.

In 2017, China’s food and drug resource-limited tropical areas. authority approved its first Such ease of storage and Ebola virus vaccine, making handling gives the Ad5-EBOV China only the second country to vaccine an edge over competing licence a vaccine for this deadly products from multinational disease. Causing a sudden pharmaceutical companies. onset of high fever, followed by With recent reports of new vomiting, diarrhoea, and internal Ebola outbreaks in Democratic and external bleeding, Ebola, Republic of the Congo, the Ad5- with mortality rates varying EBOV vaccine, already approved Chinese returnees, who held based currently available in China. vaccine products in the pipeline, conjugate vaccines. With various The company is also from 40% to 90%, has no in China for emergency use, senior management and (PBPV), represent innovative The company developed covering 12 disease areas. carrier proteins, including the equipped with state-of-the-art proven treatment so far. The could be included in international technical positions at world- vaccine products. For instance, these vaccines utilizing its Among these, six are still in pre- commonly used DT and TT animal research facilities and outbreak of Ebola virus in West emergency vaccine stockpiles. renowned pharmaceutical in using pneumococcal proteins core technologies, which clinical stage, including vaccine carrier proteins, and CRM197, has built pilot and commercial Africa in 2014-16 killed more Yu Xuefeng, chairman and companies abroad, CanSinoBIO or virulence factors to reduce the significantly improve the candidates for adenovirus, CanSinoBIO has developed manufacturing facilities to than 11,000 people. CEO of CanSinoBIO, points has now developed into a team virulence of infecting bacteria, current vaccines in use meningitis, shingles, polio, and high-quality multi-valent meet international standards. is vital for disease control. A out that from a concept of more than 300 professional PBPV is seen as next-generation globally. Examples include . It will further optimise conjugate and combination “Vaccination is an essential recombinant Ebola virus vaccine, to an approved product, R&D, commercial and technology for pneumococcal the quadrivalent (ACYW135) its product pipelines to better vaccines, standing out among its part of effective disease control jointly developed by Beijing the development of Ad5- manufacturing staff, who are on vaccines. It provides an meningococcal conjugate meet market demand. Chinese competitors. Its PCV13, and prevention,” says Yu. “Our Institute of Biotechnology EBOV vaccine took just a a quest to develop affordable, alternative to the conventional vaccine (MCV4) for protection potentially a best-in-class in ultimate goal is to make high- and CanSino Biologics Inc. little more than three years, high-quality and innovative serotype-based conjugate against from four Advanced technological China, employs a combination of quality vaccines accessible to (CanSinoBIO), a Tianjin-based demonstrating CanSinoBIO’s vaccines for people in China and vaccines that only cover limited types of meningococcal platforms different carrier proteins and is people all over the world.” company specialising in the strong capability for efficiently around the world. Its expertise number of serotypes. PBPV may bacteria, as well as DTcP- With great lab and human ready for application. To achieve its ambition, development and manufacture pushing a candidate through lies in discovery, also provide broader protection. based combo vaccines. Both resources for microbiology, With protein structure CanSinoBIO plans to raise more of human vaccines, offers a R&D and completing pre- efficient CMC development, With an anticipated simplified of these vaccines are in high molecular cell biology, design and recombinant capital through an IPO on the new tool for combating this clinical studies and clinical and a world-standard quality production process and lower demand in China. CanSinoBIO immunology and biochemistry, technology, CanSinoBIO has Hong Kong stock exchange. It devastating threat to public trials. With advanced R&D system, manufacturing system cost compared with current now completed the phase III CanSinoBIO has developed designed pneumococcal protein is also actively recruiting talent health. platforms, cutting-edge and management team. The conjugate vaccines, efforts are clinical trials for MCV4 and has advanced technologies to and engineered worldwide, seeking people with The Ad5-EBOV vaccine technologies and an efficient company has been able to push underway to translate success initiated clinical trials for DTcP. support its strong product novel recombinant strains for expertise in R&D, quality control, developed in China relies on management system, the multiple vaccine candidates in animal models to human CanSinoBIO is also pipeline. The adenovirus-based a new with manufacturing, commercial the recombinant replication- company boasts a proven track through proof-of-concept pre- vaccines. CanSinoBIO has now determined to develop its vaccine technology, significantly high yields. The operation, and more. defective human adenovirus record of success in new drug clinical evaluation and human completed pre-clinical studies own vaccines to compete used for R&D of the Ebola technology is also applied to type-5 vector to induce discovery, development and phase 1 through phase 3 clinical for its PBPV product, which is with imported products. vaccine, is a preferred strategy developing proprietary cell lines immune responses and commercialization. “We want trials. intended for use for all ages, and Pneumococcal conjugate for preventing emerging for viral vector production. provide protection against the to lead and foster the Chinese In view of the growing obtained approval for conducting vaccines (PCV13i) are currently infectious diseases. It also The formulation platform Ebola virus. Manufactured vaccine industry to become Chinese demand for vaccines, clinical trials from the Chinese in development. The pre-clinical enables CanSinoBIO to develop ensures consistent quality as a lyophilized powder, it is a major contributor to global CanSinoBIO focuses on three regulatory authority. Its TB studies have been already its TB booster and other vaccine and reduces potential risk of highly stable and does not public health,” says Yu. major product lines. The vaccine is already undergoing completed. “We are aiming at candidates. side effects. CanSinoBIO has require storage at ultra-low , along with the clinical trials in Canada. developing best-in-class vaccines The conjugation technology formulations free from any temperatures. This feature Diversified vaccine products adenovirus-based recombinant Another line of products in China for the world,” said Yu. platform allows CanSinoBIO to animal components, phenol and renders it viable for use in Founded in 2009 by four TB vaccine and the protein- is first-in-class vaccines not The company currently has 15 manufacture a wide range of preservatives. [email protected]

Advertiser retains sole responsibility for content Advertiser retains sole responsibility for content